Hi, what are you looking for?
Numinus' gross margin improved to 29.1 per cent during Q2 2022 following acquisitions of Mindspace Psychology Services Inc. and the Neurology Centre of Toronto
CEO Payton Nyquvest says the authorization moves his firm closer to developing medicines at scale to support psychedelic-assisted therapy
Health Canada's guidance on how to access illicit substances for medical purposes has been a moving target over the past year
The new rules will facilitate safer access to substances like psilocybin, but many in need won't qualify, experts say